This suggests that the effects of rapamycin can be explained in part by reducing S6K1 activity, but that additional downstream effects of mTORC1 inhibition also likely contribute to delayed mitochondrial disease progression in NKO mice at higher doses of rapamycin. Here, RPS6KB1 is linked to mitochondrial disease.